Non-small Cell Lung Cancer
Conditions
Keywords
Chinese, real-world evidences, NSCLC, surgeries
Brief summary
The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer
Detailed description
The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lung cancer and adjuvant chemotherapies will be included in the study and the study data on patient demographic/tumor biological characteristics and clinical treatment will be collected to evaluate compare effectiveness of radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies after surgeries.
Interventions
PROCEDURESurgeries
Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
Sponsors
LinkDoc Technology (Beijing) Co. Ltd.
Tang-Du Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with radical resection of lung cancer enrolled from 2014 to 2019; * Pathologically diagnosed patients with non-small cell lung cancer; * Patients with age \> 18 years old; * Patients who did not receive chest surgeries before hospitalization; * Patients with N2 lymph nodes (+) after surgeries; * Patients who received lymphadenectomy for one group or more groups of lymph nodes;
Exclusion criteria
* Patients with second primary tumors or multiple primary tumors;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 2014 - 2017 | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 2014 - 2017 | Disease-free survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| Impact factors of overall survival as measured by age | 2014 - 2017 | Impact factors of overall survival as measured by age |
| Impact factors of overall survival as measured by gender | 2014 - 2017 | Impact factors of overall survival as measured by gender |
| Impact factors of overall survival as measured by BMI | 2014 - 2017 | Impact factors of overall survival as measured by BMI |
| Impact factors of overall survival as measured by tumor size | 2014 - 2017 | Impact factors of overall survival as measured by tumor size |
| Impact factors of overall survival as measured by tumor location | 2014 - 2017 | Impact factors of overall survival as measured by tumor location |
| Impact factors of overall survival as measured by T staging | 2014 - 2017 | Impact factors of overall survival as measured by T staging |
| Impact factors of overall survival as measured by clinical treatments | 2014 - 2017 | Impact factors of overall survival as measured by surgeries plus adjuvant chemotherapies and surgeries plus perioperative chemotherapies |
| Overall survivals in the subgroups | 2014 - 2017 | Overall survivals in the subgroups categorized by T staging |
| Time to distant recurrence | 2014 - 2017 | Time to distant recurrence |
| Death rate within 30/90 days after surgeries | 2014 - 2017 | Death rate within 30/90 days after surgeries |
| Impact factors of death rate within 30/90 days after surgeries as measured by patient demographic characteristics | 2014 - 2017 | Impact factors of death rate within 30/90 days after surgeries as measured by patient demographic characteristics |
| Impact factors of death rate within 30/90 days after surgeries as measured by tumor biological characteristics | 2014 - 2017 | Impact factors of death rate within 30/90 days after surgeries as measured by tumor biological characteristics |
| Impact factors of death rate within 30/90 days after surgeries as measured by various modes of surgeries | 2014 - 2017 | Impact factors of death rate within 30/90 days after surgeries as measured by various modes of surgeries |
| Incidence of perioperative complications | 2014 - 2017 | Incidence of perioperative complications |
| Time to local recurrence | 2014 - 2017 | Time to local recurrence |
| Disease-free survivals in the subgroups | 2014 - 2017 | Disease-free survivals in the subgroups categorized by T staging |
Countries
China
Outcome results
None listed